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ABSTRACT
HIV-1 gene expression requires both viral and
cellular factors to control and coordinate transcrip-
tion. While the viral factor Tat is known for its tran-
scriptional transactivator properties, we present
evidence for an unexpected function of Tat in viral
splicing regulation. We used a series of HIV-1
reporter minigenes to demonstrate that Tat’s role
in splicing is dependent on the cellular co-tran-
scriptional splicing activators Tat-SF1 and CA150.
Surprisingly, we show that this Tat-mediated
splicing function is independent from transcriptional
activation. In the context of the full-length viral
genome, this mechanism promotes an auto-
regulatory feedback that decreases expression of
tat and favors expression of the env-specific
mRNA. Our data demonstrate that Tat-mediated
regulation of transcription and splicing can be
uncoupled and suggest a mechanism for the
involvement of specific transcriptional activators
in splicing.
INTRODUCTION
HIV-1 gene expression is a highly regulated process
composed of transcriptional and post-transcriptional
processes that are mediated by both viral and cellular
factors. The viral regulatory protein, Tat, stimulates tran-
scription elongation of HIV-1 by binding a 59-nt stem
loop structured RNA element (trans-activation-responsive
region, TAR), located at the 50-ends of all nascent HIV-1
mRNAs (1). Tat-TAR interactions promote the
recruitment of the human positive transcription elonga-
tion factor b (P-TEFb) (2). Tat interacts directly with
the cyclin T1 (CycT1) component of P-TEFb (3). The
CDK9 kinase activity of P-TEFb results in hyperphos-
phorylation at Ser2 and Ser5 positions of the RNAPII
CTD (4), which leads to eﬃcient elongation (5).
In addition, the cellular factor Tat-SF1 has been shown
to be required for eﬃcient transcriptional transactivation
(6) and has also been found to interact with spliceosomal
components (7). The association with both elongation and
splicing factors has led to the suggestion that Tat-SF1 can
couple these two processes. Tat-SF1 (Tat speciﬁc factor 1)
has been shown to be associated with other transcription
regulators such as Tat-CT1 (Tat cotransactivator 1) (8)
and the transcription-splicing coupling factor, CA150
(TCERG1, transcription elongation regulator 1) (9).
Overexpression of CA150 has been shown to reduce the
ability of Tat to mediate viral transcription (10). This
function is dependent on the association of CA150 with
pre-mRNA splicing factors and the phospho-CTD of
RNAPII (11) and may bridge splicing complexes to
actively transcribing RNAPII (12). The cellular protein
c-Ski-interacting protein, SKIP, has also been shown to
regulate Tat-dependent viral transcription and interact
with the U5 snRNPs and the tri-snRNP110K protein,
but does not associate with a number of other splicing
factors, including Tat-SF1 or CA150 (13).
The single HIV-1 primary transcript undergoes a
complex series of splicing events to generate more than
40 mRNAs (14). These messages fall into three classes:
(i) a  2kb class of multiply spliced mRNAs coding for
the viral proteins Tat, Rev and Nef, (ii) a  4kb class of
partially unspliced mRNAs coding for the viral proteins
Env, Vpu, Vif and Vpr and (iii) the 9.2kb unspliced tran-
script coding for the viral proteins Gag and Pol which are
also packaged into new virions along with the viral
genome (Figure 1A). Altering the balance of viral
mRNA splicing can have dramatic eﬀects on viral replica-
tion and infectivity (14,15). HIV-1 splicing regulation
relies on the presence of intronic and exonic sequences
as well as cellular splicing factors that interact with these
elements. To date, ﬁve exonic splicing silencers (ESS), one
intronic splicing silencer (ISS) and six exonic splicing
enhancers (ESE) have been identiﬁed (16,17). Most
cellular factors regulating viral mRNA processing
belong to either the arginine–serine rich (SR) or the
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protein families (16,18). SR proteins are structurally and
functionally related; they regulate splicing by binding
enhancer elements and recruiting and stabilizing compo-
nents of the core splicing machinery to nearby splice sites
(19). Recent work revealed that SR proteins are co-tran-
scriptionally recruited to RNAPII transcripts, coupling
transcription to splicing in vitro (20) and may promote
RNAP II elongation (21).
Work carried out in recent years indicates that tran-
scription promotes splicing (20,22,23) and reciprocally
splicing promotes transcription (7,21,24,25). The rate of
elongation, the promoter type, the transcriptional
activators present, and the chromatin remodeling factors
nearby can all aﬀect alternative splicing of a pre-mRNA
(26,27). Studies have identiﬁed several splicing factors and
spliceosomal components that interact either directly or
indirectly with the transcription machinery (24). The
carboxy-terminal domain (CTD) of the largest subunit
(Rpb1) of RNA polymerase II (RNAPII) operates as a
binding platform for components of the RNA processing
machineries (28). Nevertheless, the functional signiﬁcance
of these associations has not been fully established. We
demonstrate here that the viral factor Tat is a selective
mediator of HIV-1 transcription and splicing via interac-
tions with cellular cofactors that bridge to the RNAPII
CTD. As proper splicing is critical for transition through
stages of the viral lifecycle, this study highlights a critical
role for Tat in the regulation of viral splicing.
MATERIALS AND METHODS
Plasmids and proviral vectors
Reporter plasmid pLTR-S1Xm-R was obtained by
inserting the viral LTR promoter and the sequences
upstream of the 50ss #1 derived from the proviral
clone pNL4-3 in the construct previously described as
Figure 1. The reporter minigene mimics HIV-1 transcription and splicing regulation. (A) Schematic map of the pLTR-S1Xm-R reporter minigene.
Dashed lines indicate the location within the viral genome of the sequences utilized to build the minigene. The size of the diﬀerent fragments is
indicated on top. The Tat start codon (asterisk) is mutated (ATGm). Location of the ESE/ESS2 and GAR splicing regulatory elements are indicated
with a schematic representation of their functions. Location of the PCR primers utilized in the RT-PCR (PL1, PL2) and RT-qPCR (PR1, PR2) are
indicated. (B) Schematic representation of the main HIV-1 RNA species. Exonic sequences present in each of the main viral mRNAs are drawn in
correspondence of their location on schematic map on top. (C) Quantiﬁcation of reporter transcripts. HEK-293T cells were transfected with
pLTR-S1Xm-R, pEGFP-N1 (normalizing control) and the Tat coding plasmid pTAT. mRNAs generated by pLTR-S1Xm-R were quantiﬁed by
RT-qPCR. The arbitrary value of 1 was assigned to the amount of reporter mRNA generated in the absence of Tat. An RNA sample, which was not
reverse transcribed, was utilized as negative control ( RT). (D) Alternative spliced mRNAs generated by pLTR-S1Xm-R. HEK-293T cells were
co-transfected with pLTR-S1Xm-R, and the vector indicated on top of the ﬁgure in the presence (+) or absence ( ) of pTat. Samples were analyzed
by RT-PCR, the cDNA input for each sample was normalized on the base of the total amount of transcripts generated by the reporter construct as
determined by RT-qPCR. (E) Unspliced (US) mRNAs and the sum of all mRNA transcripts (TOT) are quantiﬁed and their ratio is indicated.
(F) mRNAs representing splicing to the tat and env speciﬁc 30ss #3 and 5 were quantiﬁed and their ratio is indicated. Data are represented as
means±SEM.
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sequence was cloned downstream. The Tat start codon
ATG was mutated into CTC. Plasmids pEVX1-S1Xm-R,
pbglo-S1Xm-R, pCMV-S1Xm-R were obtained by sub-
stituting the LTR promoter for the EVX1,  -globin and
CMVpromoters,respectively.TheEVX1and -globinpro-
moters were obtained by PCR ampliﬁcation of genomic
DNA utilizing primers EVX1-P5, EVX1-P3 and bglo-P5,
bglo-P3, respectively (primer sequences are shown in
Supplementary Table S1). The CMV promoter was
obtained by digesting the pCDN3 vector (Invitrogen) with
the restriction enzymes MluI, BamHI. Constructs
pLTR-TAR-S1Xm-R and pbGLO-TAR-S1Xm-R
were obtained by deleting the TAR region from the parent
constructs. Construct pLTR-dsx-E was obtained by
substituting the viral sequences downstream the transcrip-
tion start site in pLTR-S1Xm-R for the enhancer-
dependent splicing reporter substrate derived from the
Drosophila melanogaster dsx gene. Constructs pLTR-dsx-
GAR and pLTR-dsx-GARm were obtained inserting the
GAR and control mutated GAR sequences downstream
the second exon of the reporter substrate as previously
described (30). pLTR-Tm-dsx-GAR was obtained by
inserting a synthetic DNA fragment carrying the deletion
of the TAR stem. The pLuc plasmid was obtained by
cloning the CMV promoter upstream the luciferase gene
in the pGL4.72 vector (Promega). Plasmids pTat, pTat86,
pTat86D(1–21) pTat86R(49–57)A have been previously
described. Molecular clones pNL4-3 and pMtat( ), which
is derived from pHXB2gpt, an infectious proviral clone
of HIV-1IIIB, were obtained from the NIH AIDS
Research and Reference Reagent Program.
Cell transfections and RT-PCR analysis
Cells were transfected with Lipofectamine 2000
(Invitrogen). pEGFP-N1 (Clontech) was added to each
transfection mixture as a normalizer for transfection,
RNA extraction and RT eﬃciency. Cells were harvested
18h after transfection. Total RNA preparations were
treated extensively with DNAse to eliminate traces of
contaminating plasmids. Quantitative SYBR green
PCR analysis was performed to measure transcription
by the reporter construct with the primers PR1 and PR2
(Supplementary Table S1). qPCR analysis of the
pMtat( ) viral transcripts was performed as previously
described (15). Each sample was normalized by the
relative content in EGFP mRNA. Each assay was
carried out with a minimum of three independent
transfections while qPCR assays were carried out in dupli-
cates. Alternatively spliced mRNAs were detected using
the primers PL1, PL2 for the pLTR-S1Xm-R derived con-
structs and primers PD1, PD2 for the pLTR-dsx-R
derived constructs. Labeled ATPg
32P PCR products
were fractionated on polyacrylamide gels and visualized
by autoradiography and quantiﬁed by Kodak 1D
software. PCR analysis was performed with 26 cycles.
The amount of input cDNA was adjusted for each
sample based on the total amount of viral RNA as deter-
mined by the RT-qPCR reaction. RT-qPCR analysis of
SC35, SF2 and hnRNP A1 mRNAs were carried out using
the primer pairs 5SC35qPCR, 3SC35qPCR; 5SF2qPCR,
3SF2qPCR; 5A1qPCR, 3A1qPCR (see Supplementary
Table S1).
siRNA assay
HEK-293T cells were transfected with a mixture con-
taining 3ml of Lipofectamine 2000 (Invitrogen) and a
mixture of siRNAs 25pM each. Qiagen HP validated
siRNAs were utilized for each gene as follows: CA150
(cat. #SI04138554), (cat. #SI04328618), (cat. #SI0420
9037); Tat-SF1 (cat. #SI03154165), (cat. #SI00444479),
(cat. #SI04312896); SKIP (cat. #SI00301812), (cat.
#SI02655478), (cat. # SI00098609), Tat-CT1 (cat.
#SI04142362), (cat. #SI04144308), (cat. #SI04155816).
Forty-eight hours later cells were transfected with the
reporter construct, the indicated expression vector and a
mixture of siRNAs 10pM each. Cells were harvested and
RNA analyzed 18h later.
Immunoprecipitations and western blots
Anti-CA150 antibodies were obtained from Bethyl biolabs
(cat. #A300-360A), anti Tat-CT1 Bethyl biolabs (cat.
#A300-868A), anti-Cyclin-T1 antibodies were obtained
from Santa Cruz Biotechnology (cat. #SC1075), Tat
antibodies were obtained from Immune Technologies
(cat. #IT-001-041M), anti-aTubulin antibodies were
obtained from Sigma Aldrich (cat. #SF2 T5168),
antibody AK96 was a generous gift from Dr Adrian
Krainer (Cold Spring Harbor Laboratories), anti-SC-35
antibodies were a generous gift from Dr J. Stevenin
(INSERM, Strasbourg, France). A 50ml volume of
HeLa cell nuclear extract was diluted to 200ml( Enal
volume) with IP buﬀer [20mM HEPES (pH 7.9),
150mM KCl, 20% glycerol, 1mM dithiothreitol, 1%
Triton X-100, 0.5% NP-40, 0.2mM EDTA].
Eight-hundred picomolar of RNA substrate was added
to the reaction mixture in the samples indicated. RNA
transcripts were synthesized in vitro utilizing T7 RNA
polymerase and the following DNA oligoes substrates
TAR-WT and TAR-mut. Recombinant Tat protein was
obtained from the NIH AIDS Research and Reference
Reagent Program (cat. #2222), 150pM were added to
the reaction mixture were indicated. Then 15mgo f
anti-CA150 or anti-aTubulin antibodies were added
and the mixture was incubated with end-over-end
rotation at 4 C for 4h. Immune complexes were col-
lected by centrifugation. The pellets were washed four
times with 1ml of IP buﬀer by rotating for 5min at 4 C,
then separated by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE) gels (12.5% poly-
acrylamide) and analyzed by western blotting with the
indicated antibody.
Chromatin immunoprecipitation (ChIP) assays
HEK 293T cells seeded in six-well plates at 60–70% con-
ﬂuence were transfected with 2mg splicing reporter
minigene in the precence or absence of 1mg of Tat expres-
sion plasmid. Cells were ﬁxed with formaldehyde
(1% [vol/vol]) to crosslink the chromatin, and incubated
at room temperature for 10min. Cross-linking was
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additional 5min at room temperature. The cells were then
pelleted, washed three times with phosphate-buﬀered
saline, resuspended in SDS lysis buﬀer and incubated
10min on ice. All solutions used prior to the collection
of chromatin-antibody complexes contained protease
inhibitor cocktail. The cell lysates were sonicated 6–8
times for 20s bursts on ice. The sheared chromatin was
diluted by the addition of 10 volumes of ChIP dilution
buﬀer and pre-cleared with salmon sperm DNA–protein
A/G agarose slurry for 2h. Beads were removed by
centrifugation, 10% of the pre-cleared chromatin
supernatant was removed to serve as the pre-IP (‘input’)
control, and the remaining pre-cleared chromatin
incubated with either 10mg/ml of anti-RNAPII
(Millipore #05–623), anti-phospho ser2 RNAPII (Abcam
#ab24758), or non-speciﬁc rabbit IgG (Bethyl #P120–301)
overnight. Chromatin–antibody complexes were collected
by incubation with salmon sperm DNA–protein A/G
agarose (50% slurry) and subsequent collection of beads
by centrifugation. Bead pellets were washed in low-salt
(0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM
Tris–HCl (pH 8.0), 150mM NaCl), high-salt (0.1%
SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris–HCl
(pH 8.0), 500mM NaCl), and LiCl (0.25M LiCl, 1%
NP-40, 1% SDC, 1mM EDTA, 10mM Tris–HCl pH
8.0) immune complex wash buﬀers followed by two
washes with TE buﬀer. Antibody–chromatin complexes
were eluted from beads by incubation with elution buﬀer
(0.1% SDS, 0.1M NaHCO3). NaCl was added to eluates
(ﬁnal concentration of 0.2M) and incubated at 65 C for
4–6h. The samples were then treated with RNase A and
proteinase K, and the DNA was puriﬁed using a Qiaquick
PCR puriﬁcation kit (Qiagen). The pre-IP input sample
was puriﬁed in a manner similar to the bound ChIP
fraction described above.
Samples were ampliﬁed by PCR, with primers:
LTR-Ch-5a and LTR-Ch-3a (LTR promoter), bglo-Ch-5a
and bglo-Ch-3a (b-globin promoter), RRE-Ch-5a and
RRE-Ch-3a (ORF). Immunoprecipitate (IP) (2ml) or
input (diluted 1:3) was used in 25-ml qPCR mixtures
with primers LTR_P5ch, LTR_P3ch (LTR promoter),
bglo-Chq-5, bglo-Chq-3 ( -globin promoter) and PR1,
PR2 (ORF). Primer sequence are shown in Table 1. A
fraction of input was used to standardize the values
obtained. The relative proportions of coimmunopre-
cipitated DNA fragments were determined on the basis
of the threshold cycle (CT) for each PCR product. The
data sets were normalized to input values (percent input;
2
CT(input) – CT(IP) 100).
RESULTS
Tat expression activates splicing to the rev and env/nef
speciﬁc 30 splice sites
To study the interactions between the transcription and
splicing machineries in HIV-1, we developed the reporter
system pLTR-S1Xm-R (Figure 1A). This construct
contains the LTR promoter and a major deletion of
the ﬁrst tat intron followed by the ﬁrst Tat coding exon.
Since this reporter can code for a functional truncated Tat
protein, we mutated the Tat start ATG codon. The
mutation abrogated the Tat transactivation activity
expressed by the reporter construct (Supplementary
Figure S1). The Rev Response Element (RRE) was
added to the 30-end of the construct to provide for a
region, included in all the spliced mRNAs, that can be
detected by quantitative real time PCR (qPCR)
(Figure 1A). To determine if the reporter minigene was
responsive to Tat transactivation HEK-293T cells were
cotransfected with the pLTR-S1Xm-R construct and
either the Luciferase expression control vector pLuc or
the Tat coding vector pTat. Tat expression resulted in a
>9-fold increase in the level of the reporter minigene
mRNA (Figure 1C).
Next, we conﬁrmed that HIV-1 splicing regulation is
reliably reproduced by the reporter minigenes. We tested
the activity of cellular factors previously shown to regulate
the usage of the ﬁve alternative 30 splice sites (ss) present
within the reporter construct. Splicing to the 30ss #3 gen-
erates mRNAs coding for the Tat protein and its usage is
regulated by hnRNP A1 through binding to the splicing
silencer ESS2. The ESS2 silencer is juxtaposed to a
splicing enhancer (ESE2), which is activated by SR
proteins (Figure 1A) (31,32). Over-expression of SR
proteins SC35 and SF2 caused a shift of the splicing
pattern toward 30ss #3 while over-expression of hnRNP
A1 reduced it (Figure 1D, lanes 1–4). Although 30ss #4a–c
and 5 are regulated by an SR protein-dependent ESE
termed GAR (Figure 1A) (30) addition of SF2 or SC35
did not markedly increase their usage (Figure 1D, lane 3).
This is likely due to the relative strength of the competing
splice sites and splicing enhancers. Finally, the relative
ratio of the splicing isoforms observed was remarkably
similar to that obtained by the whole virus (15). Thus,
results indicate that the reporter construct can reliably
mimic the complex regulation of HIV-1 splicing.
Surprisingly, expression of Tat in combination with the
reporter transgene induced a switch in the splicing pattern
of the reporter. Tat expression led to a decrease in the level
of unspliced and mRNAs splicing to the 30ss #3 and an
increase in splicing to the 30ss #4a–c and 5 (Figure 1D,
lane 5; E and F). The splicing switch to the 30ss #4a–c and
5 was not observed when SC35 was co-expressed with Tat
(Figure 1D, lane 6). This is in agreement with the data
showing that SC35 binds and activates the Tat speciﬁc
30ss #3 (32).
Analysis of the endogenous mRNA for SC25, SF2 and
hnRNP A1 showed that Tat did not alter their expression
(Supplementary Figure S2). Furthermore, since a change
in the mRNA steady-state and processing can be due to an
alteration of its stability, we analyzed the relative stability
of the viral mRNAs by adding actinomycin D, an inhib-
itor of RNAPII, to the cell culture media 18h after
transfection. The viral mRNAs did not show substantial
diﬀerences in stability upon expression of any of the
proteins known to alter its splicing (Supplementary
Figure S3). These results suggested that Tat eﬀect on
splicing was not due a secondary eﬀect on mRNA stability
or expression of cellular splicing factors.
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expression of Tat, a series of Tat mutants carrying dele-
tions in domains required for its RNA binding, nuclear
localization and transactivation activities (Supplementary
Figure S4A) was co-expressed with the reporter construct.
Deletion of the Tat N-terminal domain and the
arginine-rich domain abolished both Tat transactivation
and splicing regulation activities (Supplementary Figure
S4B–E). Tat splicing activity was also disrupted by the
deletion of the TAR element, which is required for eﬃ-
cient recruitment of Tat (Supplementary Figure S5A–D).
Thus, Tat activity in viral splicing modulation appears to
be speciﬁc and dependent on a functional Tat protein and
its interaction with the viral RNA.
Tat expression regulates env gene expression
We have previously shown that a splicing enhancer
sequence, named GAR (Figure 1B), is required to stabilize
the interaction between the U1 snRNP and the down-
stream 50ss #4 and activates splicing to the upstream rev,
env speciﬁc 30ss #4a–c and 5 (30). This interaction is
required for the eﬃcient expression of env speciﬁc
mRNAs, possibly by promoting their stability and
export (33). Since our data indicate that Tat expression
promotes activation of the 30ss regulated by GAR, it is
conceivable that it might also regulate expression of env
mRNAs within the context of the complete virus. To
conﬁrm this hypothesis we utilized the proviral clone
pMtat( ), which does not express Tat (Figure 2A) (34).
HEK-293T cells were co-transfected with the proviral
vector pMtat( ) and either the control expression
plasmid pLuc or pTat. To determine the steady-state
level of the total viral mRNA, we performed RT-qPCR
with primers designed to anneal to a region common to all
viral mRNAs (Figure 2A, see P3, P4). Tat expression
increased the total viral mRNA level by 20-fold
(Figure 2B).
To quantify the single viral mRNA isoforms we utilized
primer sets spanning the splice junctions (Figure 2A). A
ﬁfth set of primers, speciﬁc for the gag/pol mRNA, was
designed to anneal immediately downstream of the major
HIV 50 splice site. Since the total amount of viral mRNA
increases upon expression of Tat, the relative amount of
the single mRNA species was normalized for the total
amount of viral mRNA present in each reaction. Tat
expression induced a 3-fold increase in the relative
amount of the env mRNA (Figure 2C) while decreasing
the tat mRNA (Figure 2E). Tat expression did not alter
the normalized amounts of gag/pol, rev and nef mRNAs
(Figure 2D, F and G).
The level of Tat expression obtained by transfection of
the pTat plasmid was comparable to the one observed in
parent proviral vector pHIV-HXB2, which carries a func-
tional Tat gene (Figure 2H). Thus, it is unlikely that the
change in the env mRNA level is due to the expression of
non-physiological amounts of Tat. Furthermore, since the
export and stability of both env and gag/pol messages are
regulated by Rev but only the relative amount of the env
mRNA is altered by Tat expression, it is likely that the
eﬀect observed is not due to the increase of Rev following
transcription transactivation. Thus, in the context of the
full virus Tat aﬀects transcription as well as expression of
speciﬁc mRNA species, consistently with the data
obtained in our reporter system.
The GAR ESE is required for Tat-mediated splicing
Splicing to the tat-speciﬁc 30ss #3 is controlled by the
juxtaposed ESE/ESS2 (31,32) while splicing to the 30ss
#4a–c and 5 is activated by the binding of SF2 to the
splicing enhancer GAR (30) (Figure 3A). Tat-mediated
splicing to the 30ss #4a–c and 5 may be due to either acti-
vation of the GAR enhancer, repression of the upstream
tat speciﬁc 30ss #3, or down-regulation of ESE2, which
activates the 30ss #3. To test these hypotheses we
mutated the diﬀerent elements that control the splicing
of this region (Figure 3A).
Mutation of the juxtaposed ESE/ESS2 decreases the
overall amount of unspliced mRNA (Figure 3B and C)
and increases usage of 30ss #3, indicating that the silencing
element is dominant toward the enhancer (Figure 3B–D,
lanes 7–12). Addition of exogenous Tat increased splicing
to the 30ss #4a–c, suggesting that Tat activates splicing
independently of the presence of the ESE/ESS2.
Furthermore, upon mutation of the tat-speciﬁc 30ss #3
addition of exogenous Tat strongly increased splicing to
the Rev/Env splice sites (Figure 3B–D, lanes 19–24). This
indicates that splicing activation by Tat is independent
from the presence of the upstream 30ss #3. On the
contrary, mutation of the GAR enhancer abolished
Tat-mediated splicing to the 30ss #4a–c and 5
(Figure 3B–D, lanes 13–18). These data suggest that Tat
is likely to regulate splicing by activating the
SF2-dependent GAR enhancer rather than repressing
usage of the upstream 30ss #3 or the ESE/ESS2 element.
Next, we sought to determine whether the GAR
enhancer might be suﬃcient to confer Tat-mediated
splicing responsiveness to a heterologous gene. To this
end, we substituted the viral sequences present between
the TAR region and the GAR element for a splicing
reporter substrate derived from the D. melanogaster
doublesex (dsx) gene (construct pLTR-dsx-GAR-R in
Figure 4A). Splicing of the parental dsx substrate
(dsx-E) is weak (Figure 4C, lanes 7 and 8) because of
a non-consensus 30ss. Insertion of an SR-dependent
splicing enhancer activates splicing by aiding in the recog-
nition of the weak splice site (35). Tat activated transcrip-
tion of the pLTR-dsx-GAR-R reporter construct similarly
to the viral reporter pLTR-S1Xm-R (Figure 4B) and
induced an increase in splicing to the weak 30ss in the
construct carrying the wild-type GAR sequence
(Figure 4C and D, lanes 1 and 2). This eﬀect was lost
upon mutation of the GAR sequence (Figure 4C and D,
lanes 3–8) or mutation of the TAR region.
Tat-mediated splicing is independent from transactivation
and Pol II CTD phosphorylation
Since Tat transactivation is dependent on enhancer motifs
present within the LTR promoter and the viral TATA box
(36), we asked if the structure of the LTR promoter would
inﬂuence Tat-mediated splicing as well. To this end,
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TAR with either the strong viral CMV promoter or
weaker cellular promoters derived from the  -globin and
EVX1 (even-skipped homeo box homolog 1 gene) genes
(Figure 5A). The transcription level from the CMV
promoter was roughly 2-fold higher than that generated
by the LTR, but the CMV promoter driven minigene was
only marginally stimulated by addition of exogenous Tat
(Figure 5B). The relative amount of transcripts generated
from the  -globin and EVX1 promoters were roughly
3–4-fold lower than that generated by the LTR; addition
of exogenous Tat did not increase the reporter mRNA
level of these minigenes (Figure 5B). Surprisingly,
analysis of the alternatively spliced mRNAs shows that
Tat can strongly mediate splicing to the 30ss #4a–c and
5 in the construct under the control of the  -globin
promoter (Figure 5D–F, lanes 13 and 14) but has a
modest eﬀect on splicing of the transcripts generated by
the CMV and the EVX1 promoters (Figure 5D–F, lanes 7,
8, 19 and 20).
Deletion of TAR in the reporter gene driven by the
 -globin promoter strongly decreased Tat mediated
splicing activity (Supplementary Figure S6) but did not
abolish it completely. A similar eﬀect was also observed
with the deletion of TAR within the reporter driven by the
LTR promoter (Supplementary Figure S5). It is possible
that a suboptimal Tat binding site distinct from TAR may
be present within the reporter transcript, thus supporting
Tat splicing activity but not its role in transcription, which
also requires the binding of Cyclin T1.
Previous work indicated that phosphorylation at Ser2
position of the RNAPII CTD stimulates transcription
elongation and pre-mRNA splicing (37,38). Since Tat
promotes RNAPII CTD phosphorylation at position
Ser2 and Ser5 (4), we investigated the phosphorylation
states of the CTD on the viral LTR versus  -globin
Figure 2. Tat upregulates env mRNA splicing. (A) Schematic representation of the pMtat( ) proviral construct. The relative position of the viral
genes is indicated on the map on top. The Tat start codon (ATG) is mutated. The main mRNAs analyzed by RT-qPCR are indicated with the solid
line representing the exons. Location of the primers utilized in the qPCR assays is also indicated (arrows P1 through P10). 50 and 30 splice sites are
indicated on the unspliced (gag/pol) mRNA. (B–G) HEK-293T cells were transfected with the proviral clone pMTat( ), the control pLuc or pTat.
Each graph summarizes the quantiﬁcation by RT-qPCR of the indicated mRNA species. The amount of each mRNA species generated in the
transfection containing the control pLuc was assigned the value 1. (B) The total viral mRNAs (primers P3–P4) data were normalized for the EGFP
mRNA content of each sample. (C–G) gag/pol mRNA (primers P1–P2), env1 mRNA (primers P5–P6), tat1 mRNA (primers P7–P8), rev2 mRNA
(primers P9–P8) and nef2 mRNA (primers P10–P8) were normalized on the base of the total viral mRNA content of each sample. A RNA sample,
which was not reverse transcribed, was utilized as negative control ( RT). (H) Tat expression in 293T cells transfected with the proviral clone
pHIV-HXB2 or cotransfected with pMTat( ) and pTat. Data are represented as means±SEM.
1254 Nucleic Acids Research, 2010, Vol.38, No. 4Figure 3. Tat-mediated splicing is dependent on the GAR ESE. (A) Schematic representation of the reporter constructs. Mechanism of ESE/ESS2
and GAR splicing splicing regulation are schematically represented. Wild-type (black bold font) and mutated (red bold font) sequences are indicated
below each construct. (B) RT-PCR analysis of alternative spliced mRNAs generated by the indicated reporter construct (top of the panel) transfected
in combination with the control (pLuc), splicing factors (pSC35, pSF2) and pTat as indicated, (C) Unspliced (US) mRNAs and the sum of all
mRNA transcripts (TOT) are quantiﬁed and their ratio is indicated. (D) The splicing products representing splicing to the tat and env speciﬁc 30ss #3
and 5 were quantiﬁed and their ratio is indicated on the left. For the pLTR-S1Xm-SS3m-R construct, products representing splicing to the env
speciﬁc 30ss #5 and unspliced mRNAs were quantiﬁed and their ratio is indicated on the right. Data are represented as means±SEM.
Figure 4. Tat promotes splicing of a heterologous substrate. (A) Schematic representation of the pLTR-dsx-R minigenes. Dsx exonic sequences (light
boxes), LTR promoter and RRE sequences (dark boxes) are shown. GAR splicing enhancer, TAR region and respective mutations are indicated. The
GAR wild type and mutated sequences are shown in Figure 3A. (B) Quantiﬁcation of reporter transcripts. HEK-293T cells were co-transfected with
the indicated reporter construct and pTat. Transcripts were quantiﬁed by RT-qPCR. A RNA sample, which was not reverse transcribed, was utilized
as negative control ( RT). (C) RT-PCR analysis of alternative spliced mRNAs generated by the indicated reporter construct (top of the panel).
(D) Spliced and unspliced mRNAs were quantiﬁed and their ratio is indicated. Data are represented as means±SEM.
Nucleic Acids Research,2010, Vol.38, No. 4 1255cellular promoter in the presence or absence of Tat. ChIP
assays were performed utilizing antibodies against the
phosphorylated form of the CTD Ser2 and against
Pol II (Figure 6). When the assay was performed on the
constructs carrying the LTR promoter in the absence of
Tat, there was association of RNAPII but not
phosphorylated Ser2 at the promoter while both, RNA
pol II and the phosphorylated Ser2, were not associated
with the downstream ORF [Figure 6A (right), B and C].
However, following addition of Tat, there was a 10-fold
increase in phosphorylated Ser2 at the promoter and an
increase in both RNAPII and its phosphorylated form at
the ORF. This indicates that Pol II stalls at the promoter
in an unphosphorylated state in the absence of Tat.
Addition of Tat promotes promoter clearance and elon-
gation through Ser2 phosphorylation. In the presence of
Figure 5. The structure of the promoter aﬀects Tat-mediated splicing. (A) Schematic representation of the reporter constructs utilized. (B)
Quantiﬁcation of reporter transcripts by RT-qPCR. HEK-293T cells were co-transfected with the indicated reporter construct, and pTat. (C)
RT-PCR analysis of alternative spliced mRNAs generated by the indicated reporter construct (top of the panel) transfected in combination with
the control (pLuc), splicing factors (pSC35, pSF2) and pTat as indicated. A RNA sample, which was not reverse transcribed, was utilized as negative
control ( RT). (D) Unspliced (US) mRNAs and the sum of all mRNA transcripts (TOT) are quantiﬁed and their ratio is indicated. (E) The splicing
products representing splicing to the tat and env speciﬁc 30ss #3 and 5 were quantiﬁed and their ratio is indicated. Data are represented as
means±SEM.
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of both RNAPII and the Ser2 phophorylated form with
the promoter and the ORF did not vary in the absence or
presence of Tat. Thus, indicating that Tat is necessary to
promote RNAPII CTD phosphorylation only in the
presence of the LTR promoter. Moreover, these diﬀer-
ences in promoter architecture reveal that Tat-mediated
splicing activation is independent from transcriptional
transactivation and phosphorylation of the RNAPII
CTD. Analysis of the relative ratios between spliced and
unspliced mRNA species (Figure 5E) also indicates that
the structure of the promoter and possibly its strength can
inﬂuence the overall splicing eﬃciency of the reporter
minigene. Indeed, the relative amount of unspliced
mRNA increased in the transcripts generated by the
 -globin and EVX1 promoters and decreased in the tran-
scripts generated by the CMV and LTR promoters
(Figure 5D and E).
Tat-mediated splicing is dependent on splicing associated
factors Tat-SF1 and CA150
Several studies have indicated a role for splicing-
associated proteins in the Tat transcription activation
complex (7,8,10,13). We investigated if proteins associated
with both the Tat transcription activation complex and
spliceosomal components are required for Tat-mediated
splicing. SiRNAs directed against components of the Tat
transactivation complex CA150, Tat-SF1, Tat-CT1 and
SKIP were co-transfected with the reporter construct in
the absence or presence of Tat. Expression of the targeted
genes was reduced by at least 70% at both RNA and
protein level (Supplementary Figure S7).
Down-regulation of Tat-SF1, induced a decrease in tran-
scription of the reporter minigenes (Figure 7A and B) and
reduced Tat-mediated splicing (Figure 7C–E, lanes 7 and
8). Reduction of CA150 expression increased basal tran-
scription of the reporter construct (Figure 7A) and par-
tially reduced Tat-mediated splicing (Figure 7C–E, lanes 9
and 10). These data suggest that Tat-mediated splicing is
dependent on both CA150 and Tat-SF1, which appear to
diﬀerentially aﬀect viral transcription conﬁrming that the
two Tat activities, transcription and splicing, might be
functionally uncoupled. This observation is conﬁrmed by
the SKIP and Tat-CT1 knockdowns, which results in a
loss of basal transcription activity (Tat-CT1 and SKIP)
and transcriptional transactivation (SKIP) (Figure 7A
and B) but not of Tat-mediated splicing (Figure 7C–E,
lanes 3–6).
Previous studies have shown that CA150 interacts
in vivo with Tat-SF1 (9). Since splicing to the 30ss #4a–c
and 5 is regulated by the SR protein-dependent splicing
enhancer GAR it is plausible that the CA150:Tat-SF1
complex might recruit SR proteins. To explore this possi-
bility we performed immunoprecipitation assays in
nuclear extracts utilizing CA150 antibodies. The assay
showed that both SR proteins, SF2 and SC35, were
co-precipitated with CA150 but not with the control
antibody (Figure 7F).
Addition to the assay mixture of an exogenous RNA
containing the TAR sequence and puriﬁed exogenous Tat
protein further increased the precipitation of SF2 and
marginally SC35 (Figure 7F–H, lane 4). The increase in
the recruitment of SR proteins was lost in the presence of
a control RNA carrying a mutated TAR sequence sug-
gesting that a complex containing CA150/Tat-SF1 and
SR proteins, in particular SF2, might be promoted by
the Tat:TAR interaction.
DISCUSSION
In this study, we show that Tat is a mediator of viral
splicing and its functions in transcriptional activation
are independent from its role in splicing regulation
(summarized in Figure 8). These observations provide
support for a general mechanism whereby transcriptional
activators, viral or cellular, can selectively regulate splicing
processes.
Prevailing models, for the coupling between the tran-
scription and the splicing machineries, propose that
splicing factors are recruited to the promoter (recruitment
model) or, alternatively, that RNAP II elongation rates
regulate the availability of competing splice sites to the
splicing machinery (kinetic model) (28,39). Both models
assign a central role to the RNAPII CTD. Diﬀerential
phosphorylation of the CTD is thought to determine the
association/dissociation of transcription and RNA pro-
cessing factors throughout the transcription cycle and to
regulate RNAPII processivity. Although, Tat promotes
the recruitment of P-TEFb to the viral promoter and
the CDK9 kinase activity of P-TEFb results in hyper-
phosphorylation of the RNAPII CTD at Ser5 and Ser2,
Figure 6. (A) RNAPII assembly and phosphorylation was analyzed by
a ChIP assay using the indicated antibodies. The location of the
primers used in the ChIP assay to analyze the promoter (black) or
ORF (gray) is schematically indicated in Figure 5A. The reporter
plasmids indicated at the left of the panel were transfected in combi-
nation or absence of Tat as indicated. Antibodies recognizing RNAPII
(RPII) and the phosphorylated form of RNAPII at Ser2 (RP-S2)
together with a control anti-IgG are indicated on top. qPCR analysis
of the RPII (B) and RP-S2 (C) assays at the promoter and ORF in the
presence or absence of Tat. The ChIP values are expressed as percent-
ages of input. Data are represented as means±SEM.
Nucleic Acids Research,2010, Vol.38, No. 4 1257our data indicate that Tat-mediated splicing may not be
dependent on this activity. Here we have shown that Tat
transactivation can be uncoupled from its splicing activity.
SubstitutionoftheLTRpromoterforheterologouscellular
( -globin, EVX1) or viral (CMV) promoters or, down-
regulation of Tat transcription co-factors cofactors
(SKIP, Tat-CT1) blocks Tat transactivation but not
splicing. Since Tat transactivation is characterized by the
hyperphosphorylation of the RNAPII CTD, which in turn
leads to eﬃcient elongation (5),ChIPassays conﬁrmed that
Tat does not promote RNAPII elongation and CTD
phosphorylation when the  -globin promoter is substituted
for the LTR. These data indicate that Tat may modulate
splicing independently from its ability to functionally
engage the transcription machinery and alter the
phosphorylation state of the RNAP II CTD.
Tat function in splicing depends on Tat-SF1 and
CA150, two cellular factors that can engage both the
Figure 7. Splicing is dependent on Tat-associated cellular factors. (A) Down-regulation by siRNA of cellular transcription-splicing factors.
HEK-293T were transfected with the reporter construct pLTR-S1Xm-R, pTat and the indicated a control siRNA (si_Cont) or siRNAs to
Tat-SF1 (si_Tat-SF1), CA150 (si_CA150), SKIP (si_SKIP), Tat-CT1 (si_Tat-CT1). Transcripts were quantiﬁed by RT-qPCR. A RNA sample,
which was not reverse transcribed, was utilized as negative control ( RT). (B) Tat transcription transactivation. Fold activation of transcription
in the presence of Tat and the indicated siRNAs. (C) RT-PCR analysis of the alternative spliced mRNAs generated by pLTR-S1Xm-R cotransfected
with either the control pLuc or pTat and the indicated siRNA (top of the panel). (D) Unspliced (US) mRNAs and the sum of all mRNA transcripts
(TOT) are quantiﬁed and their ratio is indicated. (E) The splicing products representing splicing to the tat and env speciﬁc 30ss #3 and 5 were
quantiﬁed and their ratio is indicated. (F) SF2 and SC35 co-immunoprecipitate with CA150 in HeLa nuclear extracts. CA150 was immunopre-
cipitated with anti-CA150 antibodies and anti-tubulin antibodies as control (indicated on top). Short RNA transcripts containing TAR or a control
sequence were added to the assay mixture as indicated. Recombinant GST-Tat protein was also added to the incubation mixture as indicated. The
immunoprecipitates were analyzed by western blotting with the indicated antibodies (panels from top to bottom). Quantiﬁcation of (G) SF2 and (H)
SC35 recovered in each immunoprecipitation assays. The arbitrary value of 1 was assigned to the amount recovered by precipitation with anti-CA150
antibodies in the absence of exogenous RNA and Tat. Data were quantiﬁed by optical density analysis. Data are represented as means±SEM.
1258 Nucleic Acids Research, 2010, Vol.38, No. 4splicing and transcription machineries (6,9–12).
Co-immunoprecipitation data (Figure 7F) indicate that
CA150 assembles into a complex containing SR proteins
SC35, SF2 and cyclin T1, the latter likely recruited
through the bridging activity of Tat-SF1 (40).
Furthermore, addition of Tat in the presence of the
TAR RNA appears to increase the recruitment of SF2.
Tat speciﬁcally activates the SF2 dependent GAR
enhancer but not the upstream ESE2, which is also
responsive to SF2 (Figure 3B). It is conceivable that the
relative strength and aﬃnity of the diﬀerent cis-acting
elements (ESE, ESS and splice sites) could inﬂuence this
process. Alternatively, structural constraints might also
inﬂuence the positioning of splicing factors onto the
nascent pre-mRNA. Activation of the GAR enhancer
leads to usage of the nearby 30ss #4a–c and 5 and
recruitment of U1 snRNP to the downstream 50ss #4,
which has been shown to lead to an increase expression
of the env mRNA (30). The mechanism by which
U1snRNP binding to 50ss #4 increases expression of the
env mRNA is still unclear but it is thought to increase the
stability of the viral mRNA and possibly have a
synergistic eﬀect with the Rev-dependent mRNA nuclear
export (33,41). In agreement with this model, our data
show that Tat expression speciﬁcally increases the expres-
sion of env mRNA in the context of the complete
replicating virus. This suggests a feedback model in
which higher Tat expression levels induce a
splicing-dependent increase in the relative level of
envelope protein mRNAs, which is key in infectious
virion production and viral pathogenesis.
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